Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s730. https://doi.org/10.25251/7mx6d484